
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : nCycles
Therapeutic Area : Gastroenterology
Study Phase : Discovery Platform
Recipient : Vivtex
Deal Size : Undisclosed
Deal Type : Collaboration
Orbis and Vivtex Partner To Develop Oral nCycles Drugs
Details : The collaboration will enable Orbis to utilize Vivtex’s GI-ORIS platform for gut permeability screening to evaluate the oral bioavailability of Orbis’ portfolio of next-generation macrocycle drugs.
Product Name : nCycles
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 17, 2024
Lead Product(s) : nCycles
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery Platform
Recipient : Vivtex
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Novo Holding
Deal Size : $28.1 million
Deal Type : Financing
Orbis Medicines Launches with €26 Million Seed Financing for Macrocycle Drugs
Details : The funding will support Orbis’ expansion and advancement of its next-generation macrocycle drugs, known as nCycles, designed for oral bioavailability and membrane permeability.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 29, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Novo Holding
Deal Size : $28.1 million
Deal Type : Financing
